A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Dose-dense Doxorubicin or dose-dense Epirubicin
- Registration Number
- NCT03498716
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2199
- Non-metastatic operable Stage II-III breast cancer
- Histologically documented TNBC (Triple Negative Breast Cancer)
- Confirmed tumor PD-L1 evaluation as documented through central testing of a representative tumor tissue specimen
- Adequately excised: Patients must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy
- Adequate hematologic and end-organ function
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm.
- No more than 8 weeks (56 days) may elapse between definitive breast surgery and randomization.
- Representative formalin-fixed, paraffin embedded (FFPE) tumor specimen from surgical resection in paraffin blocks (preferred) or at least 25 unstained slides.
Exclusion Criteria
- Prior history of invasive breast cancer
- For the currently diagnosed breast cancer, any previous systemic anti-cancer treatment (e.g., neoadjuvant or adjuvant), including, but not limited to, chemotherapy, anti-HER2 therapy.
- Previous therapy with anthracyclines or taxanes for any malignancy
- Cardiopulmonary dysfunction
- Prior malignancies within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Urinary outflow obstruction
- Active tuberculosis
- Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during study treatment or within 5 months following the last dose of Atezolizumab (for patients randomized to Atezolizumab)
- Prior allogeneic stem cell or solid organ transplant
- Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during the study
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Atezolizumab + Chemotherapy Atezolizumab Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Atezolizumab + Chemotherapy Dose-dense Doxorubicin or dose-dense Epirubicin Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Atezolizumab + Chemotherapy Cyclophosphamide Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Chemotherapy Paclitaxel Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Chemotherapy Dose-dense Doxorubicin or dose-dense Epirubicin Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Chemotherapy Cyclophosphamide Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Atezolizumab + Chemotherapy Paclitaxel Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
- Primary Outcome Measures
Name Time Method Invasive Disease-Free Survival (iDFS) From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years) iDFS was defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive breast cancer recurrence (an invasive breast cancer in the axilla, regional lymph nodes, chest wall, \&/or skin of the ipsilateral breast); Ipsilateral second primary invasive breast cancer; Contralateral invasive breast cancer; Distant recurrence (evidence of breast cancer in any anatomic site \[other than the sites mentioned\]) that has either been histologically confirmed \&/or clinically/radiographically diagnosed as recurrent invasive breast cancer; \& Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.
- Secondary Outcome Measures
Name Time Method Invasive Disease-Free Survival (iDFS) in the Subpopulation With Programmed Death-ligand 1 (PD-L1) Selected Tumor Status (IC1/2/3) From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years) iDFS = the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive breast cancer recurrence (an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Ipsilateral second primary invasive breast cancer, Contralateral invasive breast cancer, Distant recurrence (i.e., evidence of breast cancer in any anatomic site \[other than the sites mentioned\]) that has either been histologically confirmed and/or clinically/radiographically diagnosed as recurrent invasive breast cancer and Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.
Recurrence-Free Interval (RFI) From randomization up to 5 years Recurrence-Free Interval (RFI) was defined as the time from randomization to the first occurrence of any recurrence (local, regional \[including invasive ipsilateral tumor and invasive locoregional tumor\], or distant), as determined by investigators. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis, participants with no events who died, or participants with no post-baseline information were censored.
Disease-Free Survival (DFS) From randomization up to first disease recurrence or death from any cause (up to 5 years) Disease-Free Survival (DFS) was defined as the time from randomization to the first occurrence of disease recurrence or death from any cause. DFS events include: Ipsilateral invasive breast tumor recurrence; Ipsilateral local-regional invasive breast cancer recurrence; Distant recurrence that has either been histologically confirmed or clinically diagnosed as recurrent invasive breast cancer; Contralateral invasive breast cancer; Ipsilateral or contralateral DCIS; Second primary non-breast invasive cancer; Death attributable to any cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Patient-reported Function (Role Functioning [Q6, Q7]) Baseline (Cycle 1 Day 1), Day 1 of Cycles 4, 6, 8, 10, 12, 14 & 16; end of treatment/discontinuation (approximately at Day 351); Follow up: Months 3 to 48 (Total duration is up to 5 years); Cycles 1-5= 28 day cycles; Cycles 6-16: 21 day cycles The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. For the role functioning scale, participant responses to the 2 questions "Q6: Were you limited in doing either your work or daily activities" and "Q7: Were you limited in pursuing your hobbies or other leisure time activities" were scored on a 4-point scale (1=Not at All to 4=Very Much). The scores were linearly transformed on a scale of 0 to 100, with a low score indicating better functioning. Negative change from baseline indicated improvement.
Invasive Disease-Free Survival (iDFS) in the Node Positive Subpopulation From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years) iDFS = the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive breast cancer recurrence (an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Ipsilateral second primary invasive breast cancer; Contralateral invasive breast cancer; Distant recurrence (evidence of breast cancer in any anatomic site \[other than the sites mentioned\]) that has either been histologically confirmed and/or clinically/radiographically diagnosed as recurrent invasive breast cancer; and Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.
Overall Survival (OS) From randomization up to death from any cause (up to 5 years) Overall Survival (OS) is defined as the time from randomization to the date of death due to any cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.
Invasive Disease-Free Survival (iDFS) Including Second Primary Non-Breast Invasive Cancer From randomization up to death from any cause (up to 5 years) iDFS = the time from randomization until the date of first occurrence of one of the events: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer involving same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive breast cancer recurrence (an invasive breast cancer in axilla, regional lymph nodes, chest wall, \&/or skin of the ipsilateral breast); Ipsilateral second primary invasive breast cancer; Second primary non-breast invasive cancer; Contralateral invasive breast cancer; Distant recurrence (i.e., evidence of breast cancer in any anatomic site \[other than sites mentioned\]) that has either been histologically confirmed \&/or clinically/radiographically diagnosed as recurrent invasive breast cancer; Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.
Distant Recurrence-Free Interval (DRFI) From randomization up to 5 years Distant Recurrence-Free Interval (DRFI) was defined as the time from randomization to the distant breast cancer recurrence. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis, participants with no events who died, or participants with no post-baseline information were censored.
Change From Baseline in EORTC QLQ-C30 Global Health Status (GHS) [Q29] and Health-Related Quality of Life (HRQoL) [Q30] Combined Score Baseline (Cycle 1 Day 1), Day 1 of Cycles 4, 6, 8, 10, 12, 14 & 16; end of treatment/discontinuation (approximately 351 days); Follow up: Months 3 to 48 (Total duration is up to 5 years); Cycles 1-5= 28 day cycles; Cycles 6-16: 21 day cycles The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (Q29:GHS; "How would you rate your overall health during the past week?") and Quality of Life (Q30: QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better outcome. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement.
Number of Participants With Adverse Events (AE) Up to 5 years An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.
Change From Baseline in EORTC QLQ-C30 Patient-reported Function (Physical Functioning [Q1-Q5]) Baseline (Cycle 1 Day 1), Day 1 of Cycles 4, 6, 8, 10, 12, 14 & 16; end of treatment/discontinuation (approximately at Day 351); Follow up: Months 3 to 48 (Total duration is up to 5 years); Cycles 1-5= 28 day cycles; Cycles 6-16: 21 day cycles The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. For the physical functioning scale, participant responses to 5 questions about daily activities (strenuous activities, long walks, short walks, bed/chair rest \& needing help with eating, dressing, washing themselves, or using the toilet) were scored on a 4-point scale (1=Not at All to 4=Very Much). The scores were linearly transformed on a scale of 0 to 100, with a high score indicating worst functioning. Negative change from baseline indicated improvement in functioning.
Serum Concentration of Atezolizumab Postdose Day 1 of Cycle 1; Predose Day 1 of Cycles 2, 3, and 4; Predose Cycles 6, 10, and 14; Predose Day 2 of Cycle 16; Cycles 1-5= 28-day cycles; Cycles 6-16: 21-day cycles Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab Up to 5 years Baseline evaluable participant= participant with an ADA assay result from a baseline sample(s). Post-baseline evaluable participant= participant with an ADA assay result from at least one postbaseline sample.
Trial Locations
- Locations (364)
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
University of Maryland Greenebaum Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Royal Adelaide Hospital; Cancer Centre
🇦🇺Adelaide, South Australia, Australia
The First Hospital of Jilin University
🇨🇳Changchun City, China
Jilin Cancer Hospital
🇨🇳Changchun, China
Guangdong General Hospital
🇨🇳Guangzhou, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing City, China
Peking University People's Hospital
🇨🇳Beijing, China
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
🇨🇳Shanghai, China
Herlev Hospital; Afdeling for Kræftbehandling
🇩🇰Herlev, Denmark
Soon Chun Hyang University Cheonan Hospital
🇰🇷Dongnam-gu, Cheonan-si, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
St. Elisabeth-Krankenhaus
🇩🇪Köln, Germany
Klinikum der Universität München; Frauenklinik - Onkologie II
🇩🇪München, Germany
Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
🇩🇪Offenbach, Germany
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Martin-O?Neil Cancer Center
🇺🇸Saint Helena, California, United States
John Muir Health Clinical Research Center
🇺🇸Concord, California, United States
Baptist - MD Anderson Cancer Center
🇺🇸Jacksonville, Florida, United States
Advocate Illinois Masonic Outpatient Center for Advanced Care
🇺🇸Chicago, Illinois, United States
Cancer Center of Kansas
🇺🇸Wichita, Kansas, United States
Fairview Southdale Medical Oncology Clinic
🇺🇸Edina, Minnesota, United States
New Hampshire Hematology Oncology
🇺🇸Manchester, New Hampshire, United States
Monter Cancer Center
🇺🇸Lake Success, New York, United States
SCRI
🇺🇸Nashville, Tennessee, United States
Intermountain Precision Genomics Cancer Research Clinic-Dixie
🇺🇸Saint George, Utah, United States
Centro de Oncologia e; Investigacion Buenos Aires - COIBA
🇦🇷Berazategui, Argentina
INSTITUTO DE INVESTIGACIONES METABOLICAS (IDIM); Oncology
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Fundación Ars Medica
🇦🇷Jujuy, Argentina
Instituto de Oncología de Rosario
🇦🇷Rosario, Argentina
Centro Oncologico Riojano Integral (CORI)
🇦🇷La Rioja, Argentina
Centro de Investigacion Clinica - Clinica Viedma S.A.; Oncology Department
🇦🇷Viedma, Argentina
St Vincent's Hospital Sydney
🇦🇺Darlinghurst, New South Wales, Australia
Sydney Adventist Hospital
🇦🇺Wahroonga, New South Wales, Australia
Icon Cancer Care Wesley
🇦🇺Auchenflower, Queensland, Australia
Mater Hospital; Cancer Services
🇦🇺South Brisbane, Queensland, Australia
Icon Cancer Care South Brisbane
🇦🇺South Brisbane, Queensland, Australia
Princess Alexandra Hospital; Cancer Trials Unit
🇦🇺Woolloongabba, Queensland, Australia
Ashford Cancer Center Research
🇦🇺Kurralta Park, South Australia, Australia
Medical University Innsbruck; Frauenklinik Innsbruck, Dept Gyn
🇦🇹Innsbruck, Austria
Ordensklinikum Linz Barmherzige Schwestern; Interne 1 - Hämato-Onkologie
🇦🇹Linz, Austria
Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU
🇦🇹Salzburg, Austria
Klinikum Kreuzschwestern Wels; Iv. Interne Abt.
🇦🇹Wels, Austria
Institut Jules Bordet
🇧🇪Bruxelles, Belgium
AZ KLINA
🇧🇪Brasschaat, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Chr de La Citadelle
🇧🇪Liège, Belgium
CHC MontLégia
🇧🇪Liege, Belgium
CHU Ambroise Paré
🇧🇪Mons, Belgium
Clinique Sainte-Elisabeth; Oncologie
🇧🇪Namur, Belgium
Nucleo de Oncologia da Bahia - NOB
🇧🇷Salvador, Bahia, BA, Brazil
Instituto Nacional de Cancer - INCa; Oncologia
🇧🇷Rio de Janeiro, RJ, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Hospital Moinhos de Vento
🇧🇷Porto Alegre, RS, Brazil
Clinica de Neoplasias Litoral
🇧🇷Itajai, SC, Brazil
Hospital Amaral Carvalho
🇧🇷JAU, SP, Brazil
Faculdade de Medicina do ABC - FMABC
🇧🇷Santo Andre, SP, Brazil
Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira
🇧🇷São Paulo, SP, Brazil
Beijing Hospital; Internal Medicine-Oncology
🇨🇳Beijing, China
Beijing Union Hospital
🇨🇳Beijing, China
West China Hospital, Sichuan University
🇨🇳Chengdu, China
Merida | Investigacion Clinica
🇲🇽Mérida, Yucatan, Mexico
Chongqing Cancer Hospital
🇨🇳Chongqing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou City, China
The 900th Hospital of PLA joint service support force
🇨🇳Fuzhou, China
Sun yat-sen University Cancer Center; Internal Medicine of Oncology
🇨🇳Guangzhou, China
The Second Affiliated Hospital of Zhejiang University College
🇨🇳Hangzhou, China
Sun Yat-Sen University Cancer Center - Huangpu Campus
🇨🇳Guangzhou, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
🇨🇳Hangzhou, China
Shandong Cancer Hospital
🇨🇳Jinan, China
Luoyang Central Hospital
🇨🇳Luoyang City, China
Zhongshan Hospital Fudan University
🇨🇳Shanghai, China
The University of Hong Kong-Shenzhen Hospital; Local Ethic Committee
🇨🇳Shenzhen City, China
Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
🇨🇳Shijiazhuang, China
The First Affiliated Hospital of Xian Jiao Tong University
🇨🇳Xi'an City, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan City, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Nemocnice Horovice, NH Hospital a.s.; Oncology Department
🇨🇿Horovice, Czechia
Krajska nemocnice T. Bati, a.s.
🇨🇿Zlin, Czechia
Sygehus Lillebælt, Vejle
🇩🇰Vejle, Denmark
Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
🇨🇿Praha 2, Czechia
Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed
🇩🇰Odense C, Denmark
Centre Hospitalier Regional Metz-Thionville - Hopital de Mercy
🇫🇷Ars-Laquenexy, France
Institut Sainte Catherine
🇫🇷Avignon, France
CH de Beauvais
🇫🇷Beauvais, France
CHU Jean Minjoz
🇫🇷Besançon, France
Centre Hospitalier Fleyriat
🇫🇷Bourg-en- Bresse Cedex, France
CHRU De Brest - Hopital Morvan - Institut De Cancerologie Et D'Hematologie
🇫🇷Brest, France
Clinique Tivoli; Sce Radiotherapie
🇫🇷Bordeaux, France
Polyclinique Bordeaux Nord Aquitaine
🇫🇷Bordeaux, France
Centre Georges Francois Leclerc
🇫🇷Dijon, France
CRLCC-Francois Baclesse; Oncologie Médicale
🇫🇷Caen, France
Centre Hospitalier Bretagne Sud
🇫🇷Lorient, France
CH de Cholet; oncologie
🇫🇷Cholet, France
Centre Hospitalier de Compiegne
🇫🇷Compiegne, France
Centre Hospitalier Alpes Leman
🇫🇷Contamine Sur Arve, France
Clinique Clémentville
🇫🇷Montpellier, France
Hopital Prive Jean Mermoz
🇫🇷Lyon, France
Hôpital Saint Joseph
🇫🇷Marseille, France
Institut Jean Godinot
🇫🇷Reims, France
Institut régional du Cancer Montpellier
🇫🇷Montpellier, France
l'Hôpital privé du Confluent SAS
🇫🇷Nantes, France
CH Annecy Genevois site Annecy; Oncologie
🇫🇷Pringy, France
Centre Antoine Lacassagne
🇫🇷Nice, France
Chi De Cornouaille; Oncologie Hospitalisation
🇫🇷Quimper, France
Institut du Cancer Coulancy Reims
🇫🇷Reims, France
Centre Henri Becquerel
🇫🇷Rouen, France
Hopitaux Du Leman - Site Georges Pianta
🇫🇷Thonon Les Bains, France
Institut De Cancerologie Lucien Newrth
🇫🇷St Priest en Jarez CEDEX, France
Institut Claudius Régaud
🇫🇷Toulouse, France
Institut de Cancérologie de Lorraine
🇫🇷Vandoeuvre-Les-Nancy, France
Hopital Prive Drome Ardeche; Hopital De Jour
🇫🇷Valence, France
Institut Gustave Roussy; Departement Oncologie Medicale
🇫🇷Villejuif, France
Studienzentrum Berlin City
🇩🇪Berlin, Germany
Mordovia State University
🇷🇺Saransk, Mordovija, Russian Federation
St. Johannes-Hospital
🇩🇪Dortmund, Germany
Onkozentrum Dres. Göhler
🇩🇪Dresden, Germany
BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
🇩🇪Dresden, Germany
Albertinen-Krankenhaus Klinik f.Gynäkologie und Geburtshilfe
🇩🇪Hamburg, Germany
Ärztehaus am Bahnhofsplatz; Praxis Uleer/Pourfard
🇩🇪Hildesheim, Germany
Praxis für Hamatologie und Onkologie
🇩🇪Erfurt, Germany
Onkodok GmbH
🇩🇪Gütersloh, Germany
Klinikum Ludwigsburg; Studiensekretariat
🇩🇪Ludwigsburg, Germany
Klinikum Memmingen; Abt.Gynäkologie
🇩🇪Memmingen, Germany
St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz
🇩🇪Mainz, Germany
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
🇩🇪Mainz, Germany
Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller
🇩🇪Mayen, Germany
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
🇩🇪Mönchengladbach, Germany
Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin
🇩🇪Minden, Germany
Johanniter Frauenklinik Stendal Germany
🇩🇪Stendal, Germany
Klinikum Neumarkt; Frauenklinik
🇩🇪Neumarkt i.d.OPf., Germany
GRN-Klinik Weinheim; Abt.Gynäkologie und Geburtshilfe
🇩🇪Weinheim, Germany
Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher
🇩🇪Stralsund, Germany
Universitätsklinik Tübingen; Frauenklinik
🇩🇪Tübingen, Germany
Marien-Hospital Witten, MVZ Witten
🇩🇪Witten, Germany
Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong
Queen Elizabeth Hospital Department of Clinical Oncology
🇭🇰Kowloon, Hong Kong
National Institute of Oncology, A Dept of Internal Medicine
🇭🇺Budapest, Hungary
Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet
🇭🇺Pécs, Hungary
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház
🇭🇺Miskolc, Hungary
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Hadassah Med Org Kiryat; Oncology Institute
🇮🇱Jerusalem, Israel
Meir Medical center, Pediatrics
🇮🇱Kfar Sava, Israel
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi; UO Farmacia Clinica
🇮🇹Bologna, Emilia-Romagna, Italy
Rabin MC; Davidof Center - Oncology Institute
🇮🇱Petach Tikva, Israel
The Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Ospedale Degli Infermi - Faenza; Oncologia Medica
🇮🇹Faenza, Emilia-Romagna, Italy
Ospedale degli Infermi
🇮🇹Rimini, Emilia-Romagna, Italy
Azienda Ospedaliero Universitaria di Parma
🇮🇹Parma, Emilia-Romagna, Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Policlinico Universitario Campus Biomedico Di Roma
🇮🇹Roma, Lazio, Italy
ASST DI LECCO; Oncologia Medica
🇮🇹Lecco, Lombardia, Italy
Ospedale Mater Salutis
🇮🇹Legnago (VR), Lombardia, Italy
Fondazione Salvatore Maugeri
🇮🇹Pavia, Lombardia, Italy
Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica
🇮🇹Ponderano (BI), Piemonte, Italy
Policlinico San Mattea
🇮🇹Pavia, Lombardia, Italy
Ospedale Santa Maria Annunziata; Oncologia
🇮🇹Bagno a Ripoli, Toscana, Italy
Azienda Usl 7; Dept. Oncologico
🇮🇹Poggibonsi, Toscana, Italy
Nuovo Ospedale Di Prato
🇮🇹Prato, Toscana, Italy
Chiba Cancer Center
🇯🇵Chiba, Japan
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
🇮🇹Perugia, Umbria, Italy
Aichi Cancer Center Hospital
🇯🇵Aichi, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Hokkaido, Japan
University of Tsukuba Hospital
🇯🇵Ibaraki, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Sagara Hospital
🇯🇵Kagoshima, Japan
Tokai University Hospital
🇯🇵Kanagawa, Japan
Kyoto University Hospital
🇯🇵Kyoto, Japan
Fukushima Medical University Hospital
🇯🇵Miyagi, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Naha-nishi Clinic
🇯🇵Okinawa, Japan
National Hospital Organization Osaka National Hospital
🇯🇵Osaka, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Saitama Cancer Center
🇯🇵Saitama, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
St. Luke's Internat. Hospital, Breast Surgical Oncology
🇯🇵Tokyo, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Chungbuk National University Hospital
🇰🇷Cheongju si, Korea, Republic of
CHA Bundang Medical Center
🇰🇷Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Ewha Womans University Mokdong Hospital
🇰🇷Seoul, Korea, Republic of
Ulsan University Hosiptal
🇰🇷Ulsan, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon City, Korea, Republic of
Health Pharma Professional Research
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Wonju Christian Hospital
🇰🇷Wonju, Korea, Republic of
Centro Médico Zambrano Hellion
🇲🇽Monterrey, Nuevo LEON, Mexico
Oncologico Potosino
🇲🇽San Luis Potosí, SAN LUIS Potosi, Mexico
CENEIT Oncologicos; DENTRO DE CONDOMINIO SAN FRANCISCO
🇲🇽Mexico City, Mexico
Centro Medico Dalinde
🇲🇽Mexico City, Mexico
Instituto Nacional de Enfermedades Neoplasicas
🇵🇪Lima, Peru
Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology
🇵🇪Arequipa, Peru
Oncosalud Sac; Oncología
🇵🇪Lima, Peru
Instytut MSF Sp. z o.o.
🇵🇱?ód?, Poland
MedPolonia
🇵🇱Poznan, Poland
Wielkopolskie Centrum Onkologi
🇵🇱Poznan, Poland
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy; Klinika Onkologii
🇵🇱Warszawa, Poland
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala
🇷🇴Cluj Napoca, Romania
"Filantropia" Clinical Hospital; Gynecological Oncology
🇷🇴Bucharest, Romania
Medsi Clinic
🇷🇺Moscow, Adygeja, Russian Federation
Regional Clinical Oncology Hospital
🇷🇺Yaroslavl, Jaroslavl, Russian Federation
Bashkirian Republican Clinical Oncology Dispensary
🇷🇺UFA, Baskortostan, Russian Federation
Oncologica Dispensary #2
🇷🇺Sochi, Krasnodar, Russian Federation
Evimed
🇷🇺Chelyabinsk, Kurgan, Russian Federation
Moscow Clinical Scientific Center
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Nizhny Novgorod Regional Clinical Oncology Center
🇷🇺Nizhny Novgorod, Niznij Novgorod, Russian Federation
FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
National Medical Research Center for Oncology
🇷🇺Rostov-na-donu, Rostov, Russian Federation
LLC Strategic Medical Systems
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
EosMed LLC
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
LCC Center of Palliative Medicine - Devita
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
Regional Oncology Hospital
🇷🇺Irkutsk, Russian Federation
Ivanovo Regional Oncology Dispensary
🇷🇺Ivanovo, Russian Federation
Regional Oncology Dispensary; Dept of Chemotherapy
🇷🇺Novgorod Veliky, Russian Federation
BIH at Omsk Region "Clinical Oncology Dispensary", Outpatient clinic
🇷🇺Omsk, Russian Federation
Multidisciplinary clinic Reaviz
🇷🇺Samara, Russian Federation
Samara Regional Oncology Dispensary
🇷🇺Samara, Russian Federation
SHI Volgograd Regional Clinical Oncological Dispensary#1
🇷🇺Volgograd, Russian Federation
Regional Clinical Hospital
🇷🇺Saratov, Russian Federation
National University Hospital; Medical Oncology
🇸🇬Singapore, Singapore
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
🇪🇸Badalona, Barcelona, Spain
Hospital de Jerez
🇪🇸Jerez De La Frontera, Cadiz, Spain
National Cancer Centre
🇸🇬Singapore, Singapore
Consorci Hospitalari de Terrassa
🇪🇸Terrassa, Barcelona, Spain
Hospital Universitario Puerta de Hierro - Majadahonda
🇪🇸Majadahonda, Madrid, Spain
Hospital Provincial Castellón
🇪🇸Castellon DE LA Plana/castello DE LA Plana, Castellon, Spain
Hospital Son Llatzer
🇪🇸Palma de Mallorca, Islas Baleares, Spain
Centro Oncologico de Galicia COG; Medical Oncology
🇪🇸A Coruna, LA Coruña, Spain
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
🇪🇸Santiago de Compostela, LA Coruña, Spain
Hospital Infanta Sofia; Servico de Oncologia
🇪🇸San Sebastian de Los Reyes, Madrid, Spain
Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología
🇪🇸Vigo, Pontevedra, Spain
Hospital Universitario de Burgos
🇪🇸Burgos, Spain
Hospital Universitari Sant Joan de Reus; Planta baja, color lila
🇪🇸Reus, Tarragona, Spain
Hospital Universitario de Canarias;servicio de Oncologia
🇪🇸La Laguna, Tenerife, Spain
Hospital San Pedro De Alcantara; Servicio de Oncologia
🇪🇸Caceres, Spain
Complejo Hospitalario de Jaen
🇪🇸Jaen, Spain
Complejo Asistencial Universitario de Leon; Servicio de Oncologia
🇪🇸Leon, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Centro Integral Oncológico Clara Campal Ensayos Clínicos START
🇪🇸Madrid, Spain
Hospital Universitario de Fuenlabrada; Servicio de Oncologia
🇪🇸Madrid, Spain
Hosp Univ Fundacion Alcorcon
🇪🇸Madrid, Spain
Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
🇪🇸Murcia, Spain
Hospital Quirón Sagrado Corazón
🇪🇸Sevilla, Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Hospital General Universitario de Valencia; Servicio de oncologia
🇪🇸Valencia, Spain
Hirslanden Medical Center - Tumorzentrum
🇨🇭Aarau, Switzerland
Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia
🇪🇸Zaragoza, Spain
Centre Hospitalier Universitaire Vaudois - Lausanne
🇨🇭Lausanne, Switzerland
Chunghua Christian hospital
🇨🇳Changhua, Taiwan
Kaohsiung Medical University Hospital; Chung-Ho Memorial Hospital
🇨🇳Kaoshiung City, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei City, Taiwan
Mackay Memorial Hospital - Taipei Branch
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Rajavithi Hospital; Division of Medical Oncology
🇹🇭Bangkok, Thailand
Chang Gung Medical Foundation Linkou Branch
🇨🇳Taoyuan City, Taiwan
Siriraj Hospital; Clinical Research Center, Pharmacy Department
🇹🇭Bangkok, Thailand
Srinagarind Hospital, Khon Kaen University
🇹🇭Khon Kaen, Thailand
Lampang Cancer Hospital
🇹🇭Muang Lampang, Thailand
King Chulalongkorn Memorial Hospital; Faculty of Medicine Chulalongkorn University
🇹🇭Patumwan, Thailand
Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi
🇹🇷Adana, Turkey
Izmir Ekonomi Universitesi Medical Park Hastanesi
🇹🇷Izmir, Turkey
Uludag Universitesi - Saglik Uygulama ve Arastirrma Merkezi
🇹🇷Bursa, Turkey
Yulis Medical and Diagnostic Center
🇺🇦Zaporizhzhia, Katerynoslav Governorate, Ukraine
Medikal Park Samsun
🇹🇷Samsun, Turkey
Mersin Universitesi Tip Fakultesi Hastanesi; Tibbi Onkoloji Birimi
🇹🇷Mersin, Turkey
Municipal Institution Odesa Regional Oncology Dispensary
🇺🇦Odesa, KIEV Governorate, Ukraine
Regional Oncology Center; Department of Mammology
🇺🇦Chernigiv, Ukraine
Volyn Regional Oncology Dispensary
🇺🇦Lutsk, Ukraine
Chernivtsi Regional Clinical Oncology Dispensary
🇺🇦Chernivtsi, Ukraine
ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council; Chemotherapy Department
🇺🇦Kryvyi Rih, Ukraine
Municipal Institution Kirovograd Regional Oncology Dispensary
🇺🇦Kirovograd, Ukraine
Lviv State Oncological Regional Treatment and Diagnostic Center
🇺🇦Lviv, Ukraine
Municipal Institution Odesa Regional Clinical Hospital
🇺🇦Odesa, Ukraine
CCCH City Oncological Center SHEI Uzhgorod NU
🇺🇦Uzhgorod, Ukraine
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Leeds Teaching Hosp NHS Trust;St James's Institute of Onc
🇬🇧Leeds, United Kingdom
Zaporizhzhia Regional Clinical Oncology Dispensary; Zaporizhzhya State Medical University
🇺🇦Zaporizhzhya, Ukraine
Nottingham University Hospitals NHS Trust - City Hospital
🇬🇧Nottingham, United Kingdom
University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital
🇬🇧Stoke-On-Trent, United Kingdom
Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Icon Cancer Foundation; Icon Cancer Care Southport
🇦🇺Southport, Queensland, Australia
Maroondah Hospital; Breast Clinic
🇦🇺Ringwood East, Victoria, Australia
Clinica Universitaria Reina Fabiola
🇦🇷Cordoba, Argentina
Centro Medico San Roque
🇦🇷San Miguel de Tucuman, Argentina
P.A. Herzen Oncological Inst. ; Oncology
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Macquarie University Hospital
🇦🇺Macquarie Park, New South Wales, Australia
Klinikum Worms; Frauenklinik; Klinik für Gynäkologie und Geburtshilfe
🇩🇪Worms, Germany
Des Moines Oncology Research Association
🇺🇸Des Moines, Iowa, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Rochester General Hospital; Lipson Cancer and Blood Center
🇺🇸Rochester, New York, United States
St. Mary's Medical Center
🇺🇸Huntington, West Virginia, United States
Lismore Base Hospital
🇦🇺Lismore, New South Wales, Australia
Austin Hospital Olivia Newton John Cancer Centre
🇦🇺Heidelberg, Victoria, Australia
Icon Cancer Foundation; Icon Cancer Care Chermside
🇦🇺Chermside, Queensland, Australia
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
🇦🇹Wien, Austria
Crio - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, CE, Brazil
Vitaz
🇧🇪Sint Niklaas, Belgium
Hospital Jardim Amália
🇧🇷Volta Redonda, RJ, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
🇧🇷Ijui, RS, Brazil
Hospital Mae de Deus
🇧🇷Porto Alegre, RS, Brazil
Hospital de Cancer de Barretos
🇧🇷Barretos, SP, Brazil
Instituto Brasileiro de Controle Do Câncer ? São Camilo Oncologia
🇧🇷Sao Paulo, SP, Brazil
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Zhejiang Cancer Hospital
🇨🇳Zhejiang, China
Clinique Chenieux; Oncology
🇫🇷Limoges, France
Centre Hospitalier Departemental de Vendee
🇫🇷La Roche Sur Yon, France
Centre Paul Strauss
🇫🇷Strasbourg, France
CHU Tours - Hôpital Bretonneau
🇫🇷Tours, France
ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik
🇩🇪Karlsruhe, Germany
Pamela Youde Nethersole Eastern Hospital; Clinical Oncology
🇭🇰Hong Kong, Hong Kong
U.O Medicina Oncologica Ospedale di Carpi
🇮🇹Carpi, Emilia-Romagna, Italy
Azienda Ospedaliero - Universitaria di Modena Policlinico
🇮🇹Modena, Emilia-Romagna, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano (MI), Lombardia, Italy
Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
🇮🇹Alessandria, Piemonte, Italy
Shikoku Cancer Center
🇯🇵Ehime, Japan
Hyogo Medical University Hospital
🇯🇵Hyogo, Japan
Saitama Medical University International Medical Center
🇯🇵Saitama, Japan
Severance Hospital; Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of
Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios
🇲🇽Distrito Federal, Mexico CITY (federal District), Mexico
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Arkhangelsk Regional Clinical Oncology Dispensary
🇷🇺Arkhangelsk, Arhangelsk, Russian Federation
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
🇷🇺Saint-Petersburg, Sankt Petersburg, Russian Federation
FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
🇷🇺Saint-Petersburg, Sankt Petersburg, Russian Federation
Pyatigorsky Oncologic Dispensary
🇷🇺Pyatigorsk, Stavropol, Russian Federation
Private Healthcare Institution Clinical Hospital RZhD Medicine
🇷🇺St. Petersburg, Sankt Petersburg, Russian Federation
Hospital General De Catalunya; Servicio de Oncologia
🇪🇸Sant Cugat Del Valles, Barcelona, Spain
Brust-Zentrum Zürich AG Seefeldstrasse 214 Zürich
🇨🇭Zürich, Switzerland
City Clinical Hospital #4
🇺🇦Dnipropetrovsk, Ukraine
Vinnytsya Regional Clinical Oncology Dispensary
🇺🇦Vinnytsya, Podolia Governorate, Ukraine
MI "Clinical Oncological Dispensary" of Dnipro Reg Council; chemotherapy department
🇺🇦Dnipro, KIEV Governorate, Ukraine
Sumy Reg. Clin. Oncological Dispensary; Thoracall Department
🇺🇦Sumy, Ukraine
Transkarpathian Regional Oncology Clinic; Chemotherapy
🇺🇦Uzhgorod, Ukraine
NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital
🇬🇧Edinburgh, United Kingdom
Calderdale and Huddersfield NHS Foundation Trust
🇬🇧Huddersfield, United Kingdom
Beaumont Hospital; Cancer Clinical Trials Unit
🇮🇪Dublin, Ireland
Azienda Ospedaliero Universitaria San Martino
🇮🇹Genova, Liguria, Italy
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca de Juárez, Oaxaca, Mexico
AKH - Medizinische Universität Wien; Department of Oncology
🇦🇹Vienna, Austria
E-Da Cancer Hospital; Hematology- Oncology Department
🇨🇳Kaoshiung, Taiwan
Songklanagarind Hospital
🇹🇭Hat Yai, Thailand
Salzkammergut-Klinikum Voecklabruck
🇦🇹Vöcklabruck, Austria
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Mater Misecordiae University Hospital
🇮🇪Dublin, Ireland
Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Abruzzo, Italy
Chi Mei Medical Center Liou Ying Campus
🇨🇳Liuying Township, Taiwan
Ramathibodi Hospital; Medicine/Oncology
🇹🇭Bangkok, Thailand
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Iem-Fucam
🇲🇽D.f., Mexico CITY (federal District), Mexico
Centrul de Oncologie Sfantul Nectarie
🇷🇴Craiova, Romania
HCA Midwest Division
🇺🇸Kansas City, Missouri, United States